Safety and reactogenicity
ADVERSE EVENTS
Data regarding solicited and unsolicited adverse events (AEs) were available for all patients from diary cards (for 28 days after CoVac-1 application) and safety visits (until day 56). No patient discontinued the trial because of an AE. No vaccine-related serious adverse events (SAEs) and no grade 4 AEs were reported. Until day 56 reactogenicity in terms of solicited AEs occurred in all trial patients (Fig. 